The Enterprise welcomes the European Union (EU) commitment to increase health security in sub-Saharan Africa and Europe, building on the current partnership between the EU, its Member States and sub-Saharan countries. These partnerships are essential for facilitating research, developing and improving health technologies, which in turn contributes to reducing the burden of infectious diseases.
The Global HIV Vaccine Enterprise welcomes the important and encouraging results of the ASCENT study and new clinical data from the APPROACH study presented at the 10th IAS Conference on HIV Science (IAS 2019), held in Mexico City, Mexico. These two studies build on the success of previous research using mosaic-based vaccines and provide important data to inform ongoing efforts to develop an effective, implementable vaccine regimen – a central part of a comprehensive, global HIV prevention strategy.
The HIV vaccine field has built considerable momentum in recent times with multiple efficacy-stage programmes underway and new vaccine concepts in the clinical pipeline. The range of opportunities and possibilities is matched by a shared understanding and sense of urgency that the field is underprepared for the range of complex challenges that remain.